Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK2RIB)

Drug Name

GTB-3550 Drug Info

Synonyms

OXS-3550

Indication

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Phase 1/2	[1]
Mast cell leukaemia	2A21.00	Phase 1/2	[1]
Myelodysplastic syndrome	2A37	Phase 1/2	[1]
Systemic mastocytosis	2A21.0	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Myeloid cell surface antigen CD33 (CD33)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gemtuzumab ozogamicin	DMJ2O7B	Acute myeloid leukaemia	2A60	Approved	[3]
Vadastuximab talirine	DM9LH10	Acute myeloid leukaemia	2A60	Phase 3	[4]
Actimab-A	DMKBIPR	Acute myeloid leukaemia	2A60	Phase 2	[4]
BI-836858	DMUVMY9	Myelodysplastic syndrome	2A37	Phase 2	[5]
Actimab-MDS	DMP8EEX	Myelodysplastic syndrome	2A37	Phase 2	[6]
SGN-CD33A	DMRC7PI	Acute myeloid leukaemia	2A60	Phase 1/2	[7]
CART33 cells	DM81JIT	Myeloid leukaemia	2B33.1	Phase 1/2	[8]
CD33-specific gene-engineered T cells	DMM35D2	Acute myeloid leukaemia	2A60	Phase 1/2	[9]
Anti-CD33 CAR-T cells	DM9NPF6	Myeloid leukaemia	2B33.1	Phase 1/2	[10]
HuM-195-Ac-225	DMIU1HY	Acute myelogenous leukaemia	2A41	Phase 1/2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Immunoglobulin gamma Fc receptor III (FCGR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GMA-161	DMGVJLB	Idiopathic thrombocytopenic purpura	3B64.10	Approved (orphan drug)	[12]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Immunoglobulin gamma Fc receptor III (FCGR3)	TT7KTSR	FCG3A_HUMAN; FCG3B_HUMAN	Inhibitor	[2]
Myeloid cell surface antigen CD33 (CD33)	TTJVYO3	CD33_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03214666) GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for High Risk Heme Malignancies. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of GT Biopharma.
3	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53.
6	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals
7	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.
8	ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
9	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
10	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
11	J Clin Oncol 29: 2011 (suppl; abstr 6516).
12	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.